# Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma

> **NCT03358628** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **OTHER:** Molecular Profiling & In Vivo drug testing in PDX

## Key facts

- **NCT ID:** NCT03358628
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2020-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03358628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03358628, "Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03358628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*